Last reviewed · How we verify
SP-IPTp
SP-IPTp is a seasonal malaria chemoprevention regimen combining sulfadoxine-pyrimethamine with piperaquine to prevent malaria in pregnant women and children.
SP-IPTp is a seasonal malaria chemoprevention regimen combining sulfadoxine-pyrimethamine with piperaquine to prevent malaria in pregnant women and children. Used for Intermittent preventive treatment of malaria in pregnancy (IPTp), Seasonal malaria chemoprevention in children aged 3–59 months.
At a glance
| Generic name | SP-IPTp |
|---|---|
| Also known as | SP |
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | Antimalarial combination therapy |
| Target | Plasmodium falciparum dihydrofolate reductase (sulfadoxine-pyrimethamine); hemozoin formation (piperaquine) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | FDA-approved |
Mechanism of action
This combination therapy works by inhibiting folate metabolism (via sulfadoxine-pyrimethamine) and disrupting the malaria parasite's hemozoin formation (via piperaquine), providing prolonged antimalarial protection. SP-IPTp is administered as intermittent preventive treatment during pregnancy to reduce maternal malaria, anemia, and adverse birth outcomes, and in children as seasonal malaria chemoprevention during high-transmission periods.
Approved indications
- Intermittent preventive treatment of malaria in pregnancy (IPTp)
- Seasonal malaria chemoprevention in children aged 3–59 months
Common side effects
- Gastrointestinal disturbances
- Pruritus
- Rash
Key clinical trials
- Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda (PHASE3)
- Effectiveness, Feasibility and Acceptability of Seasonal Malaria Chemoprevention in Aweil South County in South Sudan (PHASE3)
- Chemoprevention Efficacy Study in Burkina Faso (PHASE4)
- TIPTOP Sulfadoxine-pyrimethamine (SP) Drug Resistance Study
- The ASPIRE Trial - Aiming for Safe Pregnancies by Reducing Malaria and Infections of the Reproductive Tract (PHASE3)
- Additional Screening With Sensitives RDTs and Malaria (PHASE3)
- Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG) (PHASE3)
- Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SP-IPTp CI brief — competitive landscape report
- SP-IPTp updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI